Preclinical metabolism, pharmacokinetics and in vivo analysis of new blood-brain-barrier penetrant fingolimod analogues: FTY720-C2 and FTY720-mitoxy

Keyphrases

• Activity Loss 4%
• Adrenal Gland 4%
• Age-related Illnesses 4%
• Associated Proteins 4%
• Blood-brain Barrier 100%
• Brain-to-plasma Ratio 4%
• C57BL 4%
• Carboxylic Acids 4%
• Drug Potency 4%
• Enzymatic Activity 4%
• FDA-approved Drugs 4%
• Fingolimod 100%
• FTY720 100%
• Hepatocytes 8%
• Human Liver Microsomes 4%
• Immunosuppression 4%
• In Vivo Analysis 100%
• Intravenous Delivery 4%
• Intravenous Dose 4%
• Intrinsic Clearance 4%
• Liver Microsomes 4%
• Metabolic Profiling 4%
• Metabolic Stability 4%
• Metabolism 100%
• Mitochondrial Localization 4%
• Monkey 4%
• Mouse Liver 4%
• Multiple Sclerosis 4%
• Neurodegenerative 4%
• Neuroinflammation 4%
• Neuroprotective 4%
• Octyl 4%
• Oral Dose 4%
• Oral Dosing 4%
• Orally Bioavailable 4%
• Parkinson's Disease 8%
• Peak Concentration 4%
• Penetrant 100%
• Pharmacokinetics 100%
• Phosphorylated Metabolites 4%
• Preclinical Assessment 4%
• Protein Phosphatase 2A (PP2A) 16%
• Rat Liver Microsomes 4%
• Repurposing 4%
• Sampling Time Points 4%
• Side Chain 4%
• Sphingosine-1-phosphate Receptor (S1PR) 4%
• Synucleinopathy 4%
• Translational Research 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Anti-Inflammatory Drug 3%
• Blood-Brain Barrier 100%
• C57BL 6 Mouse 3%
• Carboxylate 3%
• Diseases 3%
• Fingolimod 100%
• Haplorhini 3%
• Intrinsic Clearance 3%
• Multiple Sclerosis 3%
• Nervous System Inflammation 3%
• Neuroprotective Agent 3%
• Parkinson's Disease 7%
• Pharmacokinetics 100%
• Phosphoprotein Phosphatase 2A 15%
• Repurposing 3%
• Synucleinopathies 3%